346672-71-7

Upstream product

• 346672-67-1 5S-[4-(3-chloro-phenyl)-3-hydroxy-butyl]-1-[6-(2H-tetrazol-5-yl)-hexyl]-pyrrolidin-2-one 
• 4648-54-8 trimethylsilylazide 

Relevant academic research and scientific papers

Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension

The present invention is directed to methods for treating liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension, comprising administering to the patient in need thereof a therapeutically effective amount of a selective EP4 receptor agonist of the Formulae wherein the variables A, B, Q, ═U, and R2 for Formula l; and the variables Ar, ═M, ═N, R, W, and Z for Formula II are as defined in the specification.

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.